George S, Carrico J, Hicks KA, Loukov D, Ng C, Regan J, Giannelos N. Updated public health impact and cost effectiveness of recombinant zoster vaccine in Canadian adults aged 50 years and older. Pharmacoecon Open. 2024 Apr 11. doi: 10.1007/s41669-024-00483-w
Bali V, Schelfhout J, Sher MR, Tripathi Peters A, Patel GB, Mayorga M, Goss D, Romano (DeMuro) C. Patient-reported experiences with refractory or unexplained chronic cough: a qualitative analysis. Ther Adv Respir Dis. 2024 Mar 19;18:175346662. doi: 10.1177/17534666241236025
Salem A, La EM, Curran D, Patterson BJ, Carrico J, Lorenc S, Hicks KA, Poston S, Carpenter CF. Cost-effectiveness of recombinant zoster vaccine for the prevention of herpes zoster in hematopoietic stem cell transplant recipients and other immunocompromised adults in the United States. Pharmacoecon Open. 2023 Nov;7(6):975-85. doi: 10.1007/s41669-023-00438-7
Russell-Smith TA, Brockbank J, Mamolo C, Knight C. Cost effectiveness of gemtuzumab ozogamicin in the first-line treatment of acute myeloid leukaemia in the UK. Pharmacoecon Open. 2021 Dec;5(4):677-91. doi: 10.1007/s41669-021-00278-3
Garbinsky D, Hunter S, La EM, Poston S, Hogea C. State-level variations and factors associated with adult vaccination coverage: a multilevel modeling approach. Pharmacoecon Open. 2021 Sep;5(3):411-23. doi: 10.1007/s41669-021-00262-x
Rothwell B, Kiff C, Ling C, Brodtkorb T-H. Cost effectiveness of nivolumab in patients with advanced, previously treated squamous and non-squamous non-small-cell lung cancer in England. Pharmacoecon Open. 2021 Jun;5(2):251-60. doi: 10.1007/s41669-020-00245-4
Nagar S, Patel J, Stanford RH. Characteristics and health care resource use of subjects with COPD in the year before initiating LAMA monotherapy or LAMA+LABA combination therapy: a U.S. database study. Manag Care. 2018 May;27(5):40-7.
Meyers J, Candrilli S, Allen R, Manjunath R, Calloway M. Health care resource utilization and costs associated with restless legs syndrome among managed care enrollees treated with dopamine agonists. Manag Care. 2012 Oct 1;21(10):44-51.
Dalal AA, Candrilli SD, Davis KL. Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 ?g/50 ?g combination versus tiotropium in commercially insured patients with copd. Manag Care. 2011 Aug 1;20(8):46-55.
Iyer S, Davis KL, Candrilli S. Opioid use patterns and health care resource utilization in patients prescribed opioid therapy with and without constipation. Manag Care. 2010 Mar 1;19(3):44-51.